ArticleCureus2025
Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease more commonly found in neonates and adolescents. It can be classified as primary/genetic or acquired following viral infection, lymphomas, or autoimmune diseases. There is not enough evidence of the prevalence of this disease in adults, but, when diagnosed, it is most commonly secondary to viruses, such as Epstein-Barr virus (EBV). We report an adult case of HLH secondary to EBV in a 27-year-old Hispanic male with no significant past medical history, who presented to the emergency department with constant fatigue, myalgia, nausea, vomiting, right upper quadrant abdominal pain, and dizziness. He met six out of eight potential criteria for HLH, including splenomegaly, fever, cytopenia, hypofibrinogenemia, hyperferritinemia, and positive sCD25. He was diagnosed based on the HLH-2004 diagnostic criteria and was treated with the HLH-94 protocol. After being hospitalized for almost two months, the patient failed to respond to treatment and passed away. Prompt treatment of HLH is advised due to rapid deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.